Statins and Venous Thromboembolic Disease - Where are we Now?
Related Experiment Video
Updated: Jul 1, 2025
Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
Pavel Poredoš1, Debabrata Mukherjee2, Aleš Blinc1,3
1Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia.
Insights
Statins, used to lower cholesterol, may reduce the risk of venous thromboembolism (VTE). While promising, statin therapy should not replace standard VTE prevention or treatment methods.
Area of Science:
- Cardiovascular Medicine
- Thrombosis Research
Background:
- Classical atherosclerosis risk factors contribute to venous thromboembolism (VTE) pathogenesis.
- Low-density lipoprotein cholesterol exhibits prothrombotic and endothelium-damaging effects beyond the arterial system.
- The link between hypercholesterolemia and VTE is known, but statin efficacy for VTE prevention remains debated.
Purpose of the Study:
- To evaluate the effect of statin therapy on the incidence of venous thromboembolism (VTE).
Main Methods:
- Analysis of data from the randomized Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
- Inclusion of VTE as a protocol-specified endpoint in the JUPITER trial.
- Meta-analyses of observational studies and randomized controlled trials, including a Mendelian randomization study.
Main Results:
- The JUPITER trial showed a reduced incidence of VTE in patients taking rosuvastatin compared to placebo (HR 0.57).
- Meta-analyses corroborated these findings, indicating a protective effect of statins against VTE.
- A Mendelian randomization study confirmed a significant negative association between genetic markers for reduced statin activity and VTE incidence.
Conclusions:
- Statins demonstrate a potential protective effect against venous thromboembolism (VTE).
- The benefits of statins for VTE prevention are modest and do not warrant replacing established VTE prophylaxis or anticoagulation therapies.
Abstract:
Classical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) recorded the occurrence of VTE as a protocol-specified endpoint and reported a reduced incidence of VTE among subjects taking 20 mg of rosuvastatin daily vs placebo (hazard ratio 0.57; 95% confidence interval 0.37-0.86; p=0.007). Similar results were confirmed by meta-analyses of observation studies and randomized trials. Recently, a Mendelian randomization study that took the presence of gene variants coding for less efficient hydroxymethyl-glutaryl coenzyme A reductase activity as a proxy for statin treatment, confirmed a small, but significant negative association between the score of selected genetic polymorphisms and the incidence of VTE. However, since the protective effects of statins are limited, they should not be substituted for guideline-recommended VTE prophylaxis or anticoagulation treatment.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...